Preclinical studies suggest BCP may effectively target Parkinson’s disease and multiple sclerosis by activating the CB2 receptor and PPAR-γ, which modulate neuroinflammation, oxidative stress, and blood–brain barrier integrity. This evidence concerns the gene PPARG and multiple sclerosis.